# THNR (Amplify Weight Loss Drug & Treatment ETF)

Amplify · Thematic ETFs · data as of Sep 11, 2026

THNR holds 22 stocks, and 64% of its weight is outside the S&P 500.

## Key facts

- THNR, already in the S&P 500: 36.0%, as of Sep 11, 2026.
- THNR, active share vs the S&P 500: 96.7%, as of Sep 11, 2026.
- THNR, top ten holdings: 62.3%, as of Sep 11, 2026.
- THNR, total return, 1 year: +11.3%, as of Sep 11, 2026.
- THNR, net assets: $5m (issuer page, as of Sep 11, 2026).
- THNR, expense ratio: 0.59% (485BPOS XBRL, Jan 28, 2026).

## THNR over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +4.8% | +3.3% | +1.5 pts | +5.6 pts |
| 6 months | +5.3% | +16.0% | −10.7 pts | −15.4 pts |
| 1 year | +11.3% | +17.5% | −6.2 pts | −11.7 pts |
| Since launch | +3.4% | +47.7% | −44.3 pts | −55.3 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Healthcare innovation and GLP-1 | ETFIQ, editorial |
| Launched | May 21, 2024 | ETFIQ |
| Already in the S&P 500, by weight | 36.0% | ETFIQ |
| Active share vs the S&P 500 | 96.7% | ETFIQ |
| Already in the Nasdaq-100, by weight | 11.3% | ETFIQ |
| Active share vs the Nasdaq-100 | 98.9% | ETFIQ |
| Top ten holdings weight | 62.3% | ETFIQ |
| Holdings | 22 | ETFIQ |
| Holdings published for | Sep 14, 2026 | the issuer’s daily file |
| Top holdings | Novo Nordisk A/S 8.8%, Eli Lilly & Co 8.7%, Regeneron Pharmaceuticals Inc 6.2%, Innovent Biologics Inc 6.0%, Scholar Rock Holding Corp 5.8%, CSPC Pharmaceutical Group Ltd 5.7%, Merck & Co Inc 5.6%, AbbVie Inc 5.3%, Arrowhead Pharmaceuticals Inc 5.2%, Amgen Inc 5.1% | ETFIQ |
| Net assets | $5m | issuer page, as of Sep 11, 2026 |
| Below its all-time high | −8.3% | ETFIQ |
| Expense ratio | 0.59% | 485BPOS XBRL, Jan 28, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.61% | ETFIQ |

## Questions

### How much of THNR is in S&P 500 companies?

By its holdings published by its issuer for Sep 14, 2026, 36% of THNR by weight is stocks the S&P 500 already holds. Its active share against the index is 97%, so that share is the part doing something different.

### What does THNR hold?

22 positions as published by its issuer for Sep 14, 2026, with the top ten at 62% of the fund. The largest are Novo Nordisk A/S at 8.8%, Eli Lilly & Co at 8.7%, Regeneron Pharmaceuticals Inc at 6.2%.

### Has THNR beaten the S&P 500?

Over the year to Sep 11, 2026 THNR returned +11.3% with distributions reinvested, against +17.5% for the S&P 500, so it finished behind the index by 6.2 points.

### What does THNR cost?

The prospectus expense ratio is 0.59% a year. Because 97% of the fund differs from the S&P 500, the fee on that differing part works out at 0.61%.


## Cite this page

ETFIQ, THNR, data as of Sep 11, 2026. https://etfiq.com/funds/thnr
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/thnr  ·  JSON: https://etfiq.com/funds/thnr.json